Kim Yong Hoon, Her Ae-Young, Rha Seung-Woon, Choi Byoung Geol, Choi Se Yeon, Byun Jae Kyeong, Park Yoonjee, Kang Dong Oh, Jang Won Young, Kim Woohyeun, Choi Woong Gil, Kang Tae Soo, Ahn Jihun, Park Sang-Ho, Park Ji Young, Lee Min-Ho, Choi Cheol Ung, Park Chang Gyu, Seo Hong Seog
Division of Cardiology, Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, South Korea.
Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea.
J Geriatr Cardiol. 2019 Jun;16(6):439-447. doi: 10.11909/j.issn.1671-5411.2019.06.003.
In real practice, two or more antihypertensive drugs are needed to achieve target blood pressure. We investigated the comparative beneficial actions of combination therapy of renin-angiotensin system inhibitors (RASI), with calcium channel blockers (CCB) over CCB monotherapy on the development of new-onset diabetes mellitus (NODM) in Korean patients during four-year follow-up periods.
A total of 3208 consecutive hypertensive patients without a history of diabetes mellitus who had been prescribed CCB were retrospectively enrolled from January 2004 to December 2012. These patients were divided into the two groups according to the additional use of RASI (the RASI group, = 1221 and the no RASI group, = 1987). Primary endpoint was NODM, defined as a fasting blood glucose ≥ 126 mg/dL or hemoglobin A1c ≥ 6.5%. Secondary endpoint was major adverse cardiac events (MACE) defined as total death, myocardial infarction (MI) and percutaneous coronary intervention (PCI).
After propensity score-matched (PSM) analysis, two propensity-matched groups (939 pairs, = 1878, C-statistic = 0.743) were generated. The incidences of NODM (HR = 1.009, 95% CI: 0.700-1.452, = 0.962), MACE (HR = 0.877, 95% CI: 0.544-1.413, = 0.589), total death, MI, PCI were similar between the two groups after PSM during four years.
The use of RASI in addition to CCB showed comparable incidences of NODM and MACE compared to CCB monotherapy in non-diabetic hypertensive Korean patients during four-year follow-up period. However, large-scaled randomized controlled clinical trials will be required for a more definitive conclusion.
在实际临床中,需要两种或更多种降压药物才能达到目标血压。我们调查了肾素-血管紧张素系统抑制剂(RASI)与钙通道阻滞剂(CCB)联合治疗相较于CCB单药治疗,在韩国患者四年随访期内对新发糖尿病(NODM)发生发展的相对有益作用。
2004年1月至2012年12月,对3208例连续的无糖尿病病史且已接受CCB治疗的高血压患者进行回顾性研究。根据是否加用RASI将这些患者分为两组(RASI组,n = 1221;非RASI组,n = 1987)。主要终点为NODM,定义为空腹血糖≥126mg/dL或糖化血红蛋白≥6.5%。次要终点为主要不良心脏事件(MACE),定义为全因死亡、心肌梗死(MI)和经皮冠状动脉介入治疗(PCI)。
经过倾向评分匹配(PSM)分析,生成了两个倾向匹配组(939对,n = 1878,C统计量 = 0.743)。四年期间PSM后两组间NODM(HR = 1.009,95%CI:0.700 - 1.452,P = 0.962)、MACE(HR = 0.877,95%CI:0.544 - 1.413,P = 0.589)、全因死亡、MI、PCI的发生率相似。
在四年随访期内,对于非糖尿病的韩国高血压患者,CCB联合使用RASI与CCB单药治疗相比,NODM和MACE的发生率相当。然而,需要大规模随机对照临床试验才能得出更确切的结论。